default author photo

Siow-Ming Lee

Cancer Research UK Lung Cancer Centre of Excellence

SCHOLARLY PAPERS

2

DOWNLOADS

173

TOTAL CITATIONS

0

Scholarly Papers (2)

Actions:
Email selected abstracts
1.

IPSOS: A Phase III, Global, Multicentre, Open-Label, Randomised, Controlled Study of First-Line Atezolizumab Versus Single-Agent Chemotherapy in Patients with Non-Small Cell Lung Cancer Ineligible for Treatment with a Platinum-Containing Regimen

Number of pages: 46 Posted: 27 Dec 2022
Siow-Ming Lee, Christian Schulz, Kumar Prabhash, Dariusz Kowalski, Aleksandra Szczesna, Baohui Han, Achim Rittmeyer, Toby Talbot, David Vicente, Raffaele Califano, Diego Cortinovis, Anh Tuan Le, Dingzhi Huang, Geoffrey Liu, Federico Cappuzzo, Jessica Reyes Contreras, Martin Reck, Ramon Palmero, Milena Perez Mak, Youyou Hu, Stefanie Morris, Elen Höglander, Mary Connors, Alice M. Biggane, Hans Kristian Vollan and solange peters
Cancer Research UK Lung Cancer Centre of Excellence, University Hospital Regensburg, Tata Memorial Centre - Tata Memorial Hospital, Maria Sklodowska-Curie National Research Institute of Oncology, Mazowieckie Centrum Leczenia Chorób Płuc i Gruźlicy, Shanghai Jiao Tong University (SJTU) - Shanghai Chest Hospital, LKI Lungenfachklinik Immenhausen, Royal Cornwall Hospitals NHS Trust, Hospital Universitario Virgen Macarena, The University of Manchester - Division of Cancer Sciences, ASST - Monza - San Gerardo Hospital, Cho Ray Hospital - Cho Ray Cancer Centre, Tianjin Medical University - Tianjin Cancer Institute, University of Toronto - Princess Margaret Cancer Centre, IRCCS Regina Elena National Cancer Institute, Oncologico Potosino, San Luis Potosi, German Centre for Lung Research - Lungen Clinic Grosshansdorf, Hospital Duran i Reynals (ICO) - Catalan Institute of Oncology, University of São Paulo (USP) - Instituto do Cancer do Estado de Sao Paulo, F Hoffmann-La Roche Ltd, F Hoffmann-La Roche Ltd, F Hoffmann-La Roche Ltd, Genentech, Inc. - San Francisco, F Hoffmann-La Roche Ltd, F Hoffmann-La Roche Ltd and Centre Hospitalier Universitaire Vaudois (CHUV)
Downloads 130 (558,171)

Abstract:

Loading...

atezolizumab, PD-L1 inhibitor, IPSOS, elderly, Eastern Cooperative Oncology Group performance status (ECOG PS), non-small cell lung cancer (NSCLC), phase III, overall survival, chemotherapy, first-line, gemcitabine, vinorelbine, platinum-ineligible

2.

Outcomes in Advanced NSCLC With ECOG PS 3 at Diagnosis Ineligible for Chemotherapy: A Subgroup Analysis of the TOPICAL Randomised Trial

Number of pages: 19 Posted: 05 May 2026
Siow-Ming Lee, Simran Vaja and Allan Hackshaw
Cancer Research UK Lung Cancer Centre of Excellence, University College London - UCL Cancer Trials Centre and University College London - UCL Cancer Trials Centre
Downloads 43 (1,183,237)

Abstract:

Loading...

NSCLC, ECOG performance status 3, poor performance status, chemotherapy-ineligible, erlotinib, best supportive care, randomised trial